Natural Product Alert: Leopard Miracle of Honey may pose serious health risks
March 14, 2018
Severe cases of myocarditis have been reported in patients being treated with TECENTRIQ (atezolizumab) in clinical trials.
Healthcare professionals are advised to: monitor patients receiving TECENTRIQ for signs and symptoms of myocarditis. Withhold TECENTRIQ therapy in patients with Grade 2 myocarditis. Permanently discontinue TECENTRIQ treatment in patients with Grade 3 or 4 myocarditis. Administer corticosteroids and/or additional immunosuppressive agents as clinically indicated to TECENTRIQ treated patients who develop myocarditis. The Canadian Product Monograph has been updated to include this new safety information.